Wallin A - Search Results

1

Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting.

Wallin AK, Andreasen N, Eriksson S, Båtsman S, Nasman B, Ekdahl A, Kilander L, Grut M, Rydén M, Wallin A, Jonsson M, Olofsson H, Londos E, Wattmo C, Eriksdotter Jonhagen M, Minthon L; Swedish Alzheimer Treatment Study Group. Wallin AK, et al. Among authors: wallin a. Dement Geriatr Cogn Disord. 2007;23(3):150-60. doi: 10.1159/000098052. Epub 2006 Dec 18. Dement Geriatr Cogn Disord. 2007. PMID: 17312368 Clinical Trial.

2

Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting.

Wattmo C, Hansson O, Wallin AK, Londos E, Minthon L. Wattmo C, et al. Dement Geriatr Cogn Disord. 2008;26(3):203-11. doi: 10.1159/000152911. Epub 2008 Sep 4. Dement Geriatr Cogn Disord. 2008. PMID: 18769065 Clinical Trial.

3

Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil.

Persson CM, Wallin AK, Levander S, Minthon L. Persson CM, et al. BMC Neurol. 2009 Feb 10;9:7. doi: 10.1186/1471-2377-9-7. BMC Neurol. 2009. PMID: 19208247 Free PMC article. Clinical Trial.

4

Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.

Wattmo C, Wallin AK, Londos E, Minthon L. Wattmo C, et al. Gerontologist. 2011 Feb;51(1):17-27. doi: 10.1093/geront/gnq050. Epub 2010 Jun 20. Gerontologist. 2011. PMID: 20562471

5

Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment.

Wattmo C, Wallin ÅK, Londos E, Minthon L. Wattmo C, et al. Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):63-72. doi: 10.1097/WAD.0b013e3181f5dd97. Alzheimer Dis Assoc Disord. 2011. PMID: 20847636 Clinical Trial.

6

Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting.

Wallin AK, Wattmo C, Minthon L. Wallin AK, et al. Neuropsychiatr Dis Treat. 2011;7:565-76. doi: 10.2147/NDT.S24196. Epub 2011 Sep 30. Neuropsychiatr Dis Treat. 2011. PMID: 22003296 Free PMC article.

7

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.

Wattmo C, Wallin AK, Minthon L. Wattmo C, et al. BMC Neurol. 2012 Nov 5;12:134. doi: 10.1186/1471-2377-12-134. BMC Neurol. 2012. PMID: 23126532 Free PMC article. Clinical Trial.

8

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.

Wattmo C, Minthon L, Wallin ÅK. Wattmo C, et al. Alzheimers Res Ther. 2016 Feb 17;8:7. doi: 10.1186/s13195-016-0174-1. Alzheimers Res Ther. 2016. PMID: 26883213 Free PMC article.

9

Early-versus Late-Onset Alzheimer Disease: Long-Term Functional Outcomes, Nursing Home Placement, and Risk Factors for Rate of Progression.

Wattmo C, Wallin ÅK. Wattmo C, et al. Dement Geriatr Cogn Dis Extra. 2017 May 4;7(1):172-187. doi: 10.1159/000455943. eCollection 2017 Jan-Apr. Dement Geriatr Cogn Dis Extra. 2017. PMID: 28626471 Free PMC article.

10

Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.

Wattmo C, Wallin ÅK. Wattmo C, et al. Alzheimers Res Ther. 2017 Aug 31;9(1):70. doi: 10.1186/s13195-017-0294-2. Alzheimers Res Ther. 2017. PMID: 28859660 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

701 results

Search Page